To further investigate the role of KDM6A in lenvatinib sensitivity, we performed an in vivo tumour graft experiment by injecting Kdm6a knockdown (or SCR) Hepa1–6 cells then administered with lenvatinib. Here, KDM6A is linked to neoplasm.